ESR1 and breast carcinoma: CTC-ITB-01 cells display strongly increased HER2 levels in the presence of lapatinib (Figure 4C, right panel), indicating that potential rescue mechanisms may exist that compensate for pharmacological HER2 inhibition in ER+/HER2− breast cancer cells.